Combination therapy in female pattern hair loss

Deoghare, Shreya; Sadick, Neil S.

doi:10.1080/14764172.2023.2222942

Cited by 3 publications

(2 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Combination therapy is commonly used in the treatment of hair disorders to achieve better results, as supported by both literature and clinical practice. 8 , 9 The participants specifically selected hair injectables (82%) as the most commonly combined therapy with LDOM, followed by finasteride (74%). These findings are expected, as hair disorders in Saudi Arabia are frequently treated in private sectors where injectables are commonly used.…”

Section: Discussionmentioning

confidence: 99%

Dermatologists’ Knowledge, Attitude, and Practice Pattern Toward Low-Dose Oral Minoxidil in Hair Loss in Saudi Arabia

Altalhab

2024

CCID

View full text Add to dashboard Cite

Background The utilization of low-dose oral minoxidil (LDOM) has emerged as a relatively new treatment option for hair loss, gaining recognition among dermatologists worldwide. Objective To assess the knowledge, attitude, and practice patterns among dermatologists in Saudi Arabia regarding the use of LDOM in the management of hair loss. Methods An online survey, which was distributed to dermatologists practicing in Saudi Arabia through email and mobile messages. Both univariate and bivariate analyses were performed to investigate the factors that may be associated with enhanced knowledge and practice patterns concerning the utilization of LDOM for the management of hair loss. Results A total of 84 dermatologists was included in this study, with 50 (60%) being male. It was found that 83 (99%) of the participants identified patterned hair loss as the most common indication for LDOM usage. Additionally, 77 (92%) recognized hypertrichosis as a well-known side effect. 48 (82%) of the dermatologists had never prescribed LDOM due to its unavailability in local pharmacies. Conclusion The usage of LDOM for hair disorders is increasing. Nonetheless, many dermatologists abstain from prescribing this medication due to its limited availability in local pharmacies.

show abstract

Section: Discussionmentioning

confidence: 99%

Dermatologists’ Knowledge, Attitude, and Practice Pattern Toward Low-Dose Oral Minoxidil in Hair Loss in Saudi Arabia

Altalhab

2024

CCID

View full text Add to dashboard Cite

show abstract

“…There are also other non-FDA-approved treatments that show effectiveness in patients with AGA. These include, among others, hormonal therapies with antiandrogenic effects: oral spironolactone, bicalutamide, cyproterone acetate (CA), and topical androgen receptor inhibitors: clascoterone and pyrilutamide [ 23 , 26 , 43 , 44 ]. Spironolactone, a synthetic aldosterone receptor antagonist, also acts as an AR antagonist and decreases total testosterone levels by blocking adrenal enzymes involved in the synthesis of T (17α-hydroxylase and desmolase) [ 45 , 46 ].…”

Section: Androgensmentioning

confidence: 99%

The Hormonal Background of Hair Loss in Non-Scarring Alopecias

Owecka,

Tomaszewska,

Dobrzeniecki

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Hair loss is a common clinical condition connected with serious psychological distress and reduced quality of life. Hormones play an essential role in the regulation of the hair growth cycle. This review focuses on the hormonal background of hair loss, including pathophysiology, underlying endocrine disorders, and possible treatment options for alopecia. In particular, the role of androgens, including dihydrotestosterone (DHT), testosterone (T), androstenedione (A4), dehydroepiandrosterone (DHEA), and its sulfate (DHEAS), has been studied in the context of androgenetic alopecia. Androgen excess may cause miniaturization of hair follicles (HFs) in the scalp. Moreover, hair loss may occur in the case of estrogen deficiency, appearing naturally during menopause. Also, thyroid hormones and thyroid dysfunctions are linked with the most common types of alopecia, including telogen effluvium (TE), alopecia areata (AA), and androgenetic alopecia. Particular emphasis is placed on the role of the hypothalamic–pituitary–adrenal axis hormones (corticotropin-releasing hormone, adrenocorticotropic hormone (ACTH), cortisol) in stress-induced alopecia. This article also briefly discusses hormonal therapies, including 5-alpha-reductase inhibitors (finasteride, dutasteride), spironolactone, bicalutamide, estrogens, and others.

show abstract

Medical Treatment for Androgenetic Alopecia

Panchaprateep

2023

Facial Plast Surg

View full text Add to dashboard Cite

Androgenetic alopecia (AGA) is a common type of hair loss, which is generally influenced by genetic factors and systemic androgens resulting in follicular miniaturization1. It can cause cosmetic problems leading to psychological distress among affected men and women. Effective standard medical treatments available are topical minoxidil 2-5%, oral finasteride, oral dutasteride, and hair transplantation.1 However, some patients do not achieve favorable results with standard treatments. For these reasons, other novel treatments have been developed, including new medications, regenerative medicines (autologous platelet-rich plasma (PRP), adipose derived stem cells, micrograft generation and exosome) and low-level laser therapy (LLLT).

show abstract

Combination therapy in female pattern hair loss

Cited by 3 publications

References 39 publications

Dermatologists’ Knowledge, Attitude, and Practice Pattern Toward Low-Dose Oral Minoxidil in Hair Loss in Saudi Arabia

Dermatologists’ Knowledge, Attitude, and Practice Pattern Toward Low-Dose Oral Minoxidil in Hair Loss in Saudi Arabia

The Hormonal Background of Hair Loss in Non-Scarring Alopecias

Medical Treatment for Androgenetic Alopecia

Contact Info

Product

Resources

About